BioStabilization Systems (BoSS)

cell and gene therapies (CGTs): the critical dependence on ultra-cold conditions (-80 to -196?C) for storage and transport. BoSS will yield a bioprocessing system that enables scalable production of thermally stable cells, paving the way for a new era of efficient and resilient manufacturing and di

stribution of biologics without any need for cold storage. BoSS-developed technologies will also accelerate many other avenues in biotechnology that directly impact healthcare, including bio-surveillance, regenerative medicine, large-scale